title: Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data.
abstract: A major goal of cancer genome sequencing is to identify mutations or other somatic alterations that can be targeted by selective and specific drugs. dGene is an annotation tool designed to rapidly identify genes belonging to one of ten druggable classes that are frequently targeted in cancer drug development. These classes were comprehensively populated by combining and manually curating data from multiple specialized and general databases. dGene was used by The Cancer Genome Atlas squamous cell lung cancer project, and here we further demonstrate its utility using recently released breast cancer genome sequencing data. dGene is designed to be usable by any cancer researcher without the need for support from a bioinformatics specialist. A full description of dGene and options for its implementation are provided here.
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America ; Computational and Systems Biology Program, Division of Biology and Biomedical Sciences, Washington University in St. Louis, St. Louis, Missouri, United States of America.
authors.forename: Runjun D
authors.initials: RD
authors.lastname: Kumar
authors.forename: Li-Wei
authors.initials: LW
authors.lastname: Chang
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Ellis
authors.forename: Ron
authors.initials: R
authors.lastname: Bose
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D019295:Computational Biology; D015894:Genome, Human; D006801:Humans; D058977:Molecular Sequence Annotation; D009154:Mutation; D009369:Neoplasms / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide
chemical_list: D000970:Antineoplastic Agents